SW
DGX icon

SlateStone Wealth’s Quest Diagnostics DGX Stock Holding History

SlateStone Wealth’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-4,190
Closed -$447K – 184
2019
Q4 		$447K Sell
4,190
-165
-4% -$17.2K 0.1% 142
2019
Q3 		$466K Buy
+4,355
New +$447K 0.14% 108

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
FMI
Fiduciary Management Inc Milwaukee, Wisconsin $8.06B AUM 6.78% 1-Year Est. Return
DSA
Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SlateStone Wealth's DGX Position: Q1 2020 in Review

SlateStone Wealth sold out of Quest Diagnostics (DGX) in Q1 2020, closing a stake of 4,190 shares — an estimated $447K sold.

SlateStone Wealth first reported a position in DGX in Q3 2019 and held it in 2 quarters. The position peaked at $466K in Q3 2019. 714 funds tracked by Wall St. Rank hold DGX as of Q1 2020.

  • SlateStone Wealth reported no remaining Quest Diagnostics position as of Q1 2020 after selling out during the quarter.
  • SlateStone Wealth sold 4,190 Quest Diagnostics shares in Q1 2020, an estimated $447K.
  • SlateStone Wealth first reported a position in Quest Diagnostics in Q3 2019 and held it in 2 quarters.
  • SlateStone Wealth's Quest Diagnostics position peaked at $466K in Q3 2019.
  • 714 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2020.

Based on SlateStone Wealth's 13F filing for Q1 2020, filed 28 Apr 2020.